Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond Journal Article
| Authors: | Ladanyi, M.; Pao, W. |
| Article Title: | Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond |
| Abstract: | Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific cancers and these mutant proteins are proving to be excellent substrates for targeted therapies. This is the case for mutant EGFR-dependent lung adenocarcinomas, where EGFR mutation testing is already being used to help guide treatment decisions. Here, we provide an overview of the biology of EGFR-targeted therapies and the clinical experience to date, the positive and negative predictors of response, pathologic correlates of EGFR-mutant status, testing methods to establish patient eligibility for these agents, and the basis for primary and secondary resistance. © 2008 USCAP, Inc All rights reserved. |
| Keywords: | epidermal growth factor; mitogen activated protein kinase; gene mutation; mutation; review; erlotinib; antineoplastic agents; clinical trials as topic; drug targeting; adenocarcinoma; gene amplification; carcinoma, non-small-cell lung; lung neoplasms; gene frequency; receptor, epidermal growth factor; protein tyrosine kinase; mutational analysis; histology; drug delivery systems; protein kinase inhibitors; lung adenocarcinoma; fluorescence in situ hybridization; gefitinib; egfr; kras; trastuzumab; ligand binding; braf; non-small cell lung carcinoma |
| Journal Title: | Modern Pathology |
| Volume: | 21 |
| Issue: | Suppl. 2 |
| ISSN: | 0893-3952 |
| Publisher: | Nature Research |
| Date Published: | 2008-05-01 |
| Start Page: | S16 |
| End Page: | S22 |
| Language: | English |
| DOI: | 10.1038/modpathol.3801018 |
| PUBMED: | 18437168 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 40" - "Export Date: 17 November 2011" - "CODEN: MODPE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work